Parallel use of by-passing agents in haemophilia with inhibitors: A critical review

British Journal of Haematology

Volumn 155, Issue 2, 2011, Pages 256-262

  Ingerslev, Jørgen ^a   Sørensen, Benny ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Activated prothrombin complex concentrate; Bypassing agents; Haemophilia; Inhibitors; Recombinant activated factor VII

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 9 COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; CONGENITAL DISORDER; CONGENITAL HEMOPHILIA; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; FATALITY; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LUNG EMBOLISM; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

EID: 80053570793     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08854.x     Document Type: Article

References (42)

1. Abshire, T. & Kenet, G. (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII and IX inhibitors. Journal of Thrombosis and Haemostasis, 2, 899-909.
2. Allen, G.A., Hoffman, M., Roberts, H.R. & Monroe, D.M. (2006) Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. British Journal Haematology, 13, 314-319.
3. Balkan, C., Karapinar, D., Aydogdu, S., Ozcan, C., Ay, Y., Akin, M. & Kavakli, K. (2010) Surgery in severe haemophilia with high responding inhibitors: the Izmir experience. Haemophilia, 16, 902-909.
4. Berntorp, E., Shapiro, A., Astermark, J., Blanchette, V.S., Collins, P.W., DiMichele, D., Escuriola, C., Hay, C.R., Hoots, W.K., Leissinger, C.A., Negrier, C., Oldenburg, J., Peerlinck, K., Reding, M.T. & Hart, C. (2006) Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia, 12(Suppl. 6), 1-7.
5. Brown, S., Griffin, S., Brady, K., Poulsden, W. & Lockwood, L. (2007) Pulmonary embolism complicating sequential therapy with Novoseven and FEIBA for a high titre F VIII inhibitor in a 6year old with severe haemophilia A. Annual Meeting of the Australasian Society of Thrombosis and Haemostasis, Abstract Book: Abstract P28. Australasian Society of Thrombosis and Haemostasis 2007, ()
6. Dai, L., Bevan, D., Rangarajan, S., Sørensen, B. & Mitchell, M. (2011) Stabilization of fibrin clots by activated prothrombin compolex concentrate and tranexamic acid in FVIII inhibitor plasma. Haemophilia. DOI.
7. Dargaud, Y., Negrier, C. & Bordet, J.C. (2006) Basic aspects of bypassing agents. Haemophilia, 12 (Suppl.6), 48-53.
8. Dargaud, Y., Lienhart, A. & Negrier, C. (2010) Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood, 116, 5734-5737.
9. Diness, V., Bregengaard, C., Erhardtsen, E. & Hedner, U. (1992) Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thrombosis Research, 67, 233-241.
10. Dunkley, S.M. & Yang, K. (2009) The use of combination FEIBA and rFVIIa bypassing therapy, with TEG profiling, in uncontrollable bleeding associated with acquired haemophilia A. Haemophilia, 15, 828-830.
11. Economou, M., Teli, A., Tzantzaroudi, A., Tsatra, I., Zavitsanakis, A. & Athanassiou-Metaxa, M. (2008) Sequential therapy with activated prothrombin compolex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding. Haemophilia, 14, 390-391.
12. Gringeri, A., Fischer, K., Karafouilidou, A., Klamroth, R., Lopez- Fernandez, M.F. & Mancuso, E. on behalf of the European Haemophilia Treatment Standardisation Board. (2011) Sequential combined bypassing therapy is safe and efficacious in the treatment of unresponsive bleedings in adults and children with haemophilia and inhibitors. Haemophilia. DOI: .
13. Hay, C.R.M., Brown, S., Collins, P.W., Keeling, D.M. & Liesner, R. (2006) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. British Journal of Haematology, 133, 591-605.
14. Huth-Kühne, A., Baudo, F., Collins, P., Ingerslev, J., Kessler, C.M., Levesque, H., Castellano, M.E., Shima, M. & St-Louis, J. (2009) International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica, 94, 566-575.
15. Hvas, A.M., Sørensen, H.T., Norengaard, L., Christiansen, K., Ingerslev, J. & Sørensen, B. (2007) Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe haemophilia. Journal of Thrombosis and Haemostasis, 12, 2408-2414.
16. Ingerslev, J. (2000) Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procesures in hemophilic patients with factor VIII and factor IX inhibitors. Seminars in Thrombosis and Hemostasis, 26, 425-432.
17. Kempton, C.L. & White, G.C. 2nd (2009) How we treat a hemophilia A patient with a factor VIII inhibitor. Blood, 113, 11-17.
18. Key, N.S., Christie, B., Henderson, N. & Nelsestuen, G.L. (2002) Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in haemophilia therapy. Thrombosis and Haemostasis, 88, 60-65.
19. Knight, C., Danø, A.M. & Kennedy-Martin, T. (2009) Systematic review of efficacy of rFVIIa and aPCC treatmentfor haemophilia patients with inhibitors. Advances in Therapy, 26, 68-88.
20. Kraut, E.H., Aledort, L.M., Arkin, S., Stine, K.C. & Wong, W.Y. (2007) Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Haemophilia, 13, 508-517.
21. Livnat, T., Martinowitz, U., Zivelin, A. & Seligsohn, U. (2008) Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia, 14, 782-786.
22. Livnat, T., Martinowitz, U., Zivelin, A., Rima, D. & Kenet, G. (2011) A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in patients with an inhibitor. Blood Coagulation and Fibrinolysis, 105, in press.
23. Martinowitz, U., Livnat, T., Zivelin, A., Luboshitz, J., Seligsohn, U. & Kenet, G. (2005) Concomitant infusion of low doses of rFVIIa and FEIBA in severe hemophilia A patients with an inhibitor to factor VIII who are refractory to rFVIIa or FEIBA has an excellent hemostatic effect and synergistically enhances thrombin generation. Journal of Thrombosis and Haemostasis, 3(Suppl. 1), Abstract P0637.
24. Martinowitz, U., Livnat, T., Zivelin, A. & Kenet, G. (2009) Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia, 15, 904-910.
25. Miranda, G.G. & Rodgers, G.M. (2009) Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA. Haemophilia, 15, 383-385 (Letter).
26. Monahan, P.E. & Gold, S.H. (2005) Recurrent hemarthrosis halted by sequential therapy with activated prothrombin complex concentrate (aPCC) and recombinant factor VIIa. Journal of Thrombosis and Haemostasis, 3(Suppl. 1), Abstract P0836.
27. Nakatomi, Y., Nakashima, T., Gokudan, S., Miyazaki, H., Tsuji, M., Hanada-Dateki, T., Araki, T., Tomokiyo, K., Hamamoto, T. & Ogata, Y. (2010) Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent. Thrombosis Research, 125, 457-463.
28. Ng, J.H., Loh, Y.S.M., Tan, D.C.L. & Lee, L.H. (2004) Thrombosis associated with use of recombinant activated factor VII: profiling two events. Thrombosis and Haemostasis, 92, 1448-1449.
29. Rosenfeld, S.B., Watkinson, K.K., Thompson, B.H., Macfarlane, D.E. & Lentz, S.R. (2002) Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thrombosis and Haemostasis, 87, 925-926.
30. Rothschild, C., Dupic, L., Harroche, A., Torchet, M.F., Aouba, A., Abadie, V. & Chalouhi, C. (2008) Dramatic effect of sequential bypassing agent treatment for a life-threatening bleeding in an infant with severe hemophilia and inhibitor. Blood, 112, Abstract 4501.
31. Schneiderman, J., Nugent, D.J. & Young, G. (2004) Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia, 10, 347-351.
32. Schneiderman, J., Rubin, E., Nugent, D.J. & Young, G. (2007) Sequental therapy with activated prothrombin complex concentrates and recombinant F VIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia, 13, 244-248.
33. Sørensen, B. & Ingerslev, J. (2004a) Thrombelastography and recombinant factor VIIa - haemophilia and beyond. Seminars in Haematology, 41(Suppl. 1), 140-144.
34. Sørensen, B. & Ingerslev, J. (2004b) Whole blood clot formation phenotypes in haemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. Journal of Thrombosis and Haemostasis, 2, 102-110.
35. Sørensen, B. & Ingerslev, J. (2006) A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant VIIa or activated prothrombin complex concentrate. Thrombosis and Haemostasis, 96, 446-453.
36. Sørensen, B. & Ingerslev, J. (2010) Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitors. Clinical outcome and laboratory observations. Thrombosis and Haemostasis, 103, 1275-1276.
37. Sørensen, B., Spahn, D.R., Innerhofer, P., Spannagl, P. & Rossaint, R. (2011) Prothrombin complex concentrates: evaluation of safety and thrombogenicity. Critical Care, 15, 201-210.
38. Stockschläder, M., Ruf, L., Linderer, A., Schroeder, T., Knoefel, W.T., Haas, R., Giers, G., Gerhardt, A., Sucker, C., Zotz, R.B. & Scharf, R.E. (2009) Induction of tolerance after combined immunosuppression and -adsorption in two patients with acquired haemophilia after severe haemorrhages controlled by sequential administration of rFVIIa and FEIBA. Thrombosis and Haemostasis, 101, 586-590.
39. Teitel, J., Berntorp, E., Collins, P., d'Orion, R., Ewenstein, B., Gomperts, E., Goudemand, J., Gringeri, A., Key, N., Leissinger, C., Monahan, P. & Young, G. (2007) A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia, 13, 256-263.
40. Turecek, P.L., Varadi, H., Gritsch, H. & Schwarz, H.P. (2004) Feiba: mode of action. Haemophilia, 10(Suppl. 2), 3-9.
41. Wegert, W., Harder, S., Bassus, S. & Kirchmaier, C.M. (2005) Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa. Platelets, 16, 45-50.
42. Young, G., Blain, R., Nakagawa, P. & Nugent, D.J. (2006) Individualization of bypassing agent treatment for haemophilia patients with inhibitors utilizing thrombelastography. Haemophilia, 12, 598-604.